# US 2021/0261573 A1 · Compositions and methods for inhibiting arginase activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0261573 A1
- Document ID: US20210261573A1
- Status: Published application
- Kind: A1
- Application number: 17/153,804
- Filed: 2021-01-20
- Published: 2021-08-26
- Earliest claimed: 2016-12-22
- Assignees: Calithera Biosciences, Inc.
- Applicants: Calithera Biosciences, Inc.
- Inventors: Eric B. SJOGREN; Jim LI; Lijing CHEN; Roland J. BILLEDEAU; Timothy F. STANTON; Michael VAN ZANDT; Darren WHITEHOUSE; Gunnar E. JAGDMANN, JR.; Lene Raunkjaer PETERSEN
- Web page: https://patentgrep.com/patent/US20210261573A1

## CPC

- C07F 5/025: {Boronic and borinic acid compounds}
- A61K 31/4245: Oxadiazoles
- A61K 31/69: Boron compounds
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.

## Claims

### Claim 1

A compound having a structure of formula (I′″):
or a pharmaceutically acceptable salt thereof;
wherein:
Rb is H or is a group selected from alkyl, alkenyl, alkynyl, acyl, —C(O)O(alkyl), and —C(O)O(aryl), wherein said group is optionally substituted by one or more substituents selected from hydroxy, halo, haloalkyl, alkoxy, —SH, —S-(alkyl), —SeH, —Se-(alkyl), aryl, heteroaryl, cycloalkyl, heterocycloalkyl, amino, carboxylic acid, ester, guanidino, and amido;
X is O or S;
R1 and R2 are each independently selected from H or a group selected from alkyl, alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl, wherein said group is optionally substituted by one or more substituents selected from hydroxy, halo, haloalkyl, alkoxy, —SH, —S-(alkyl), —SeH, —Se-(alkyl), aryl, heteroaryl, cycloalkyl, heterocycloalkyl, amino, carboxylic acid, ester, guanidino, and amido; or
R1 and R2 are taken together with the intervening atoms to form a 3- to 7-membered ring, wherein the 3- to 7-membered ring is optionally substituted with one or more substituents selected from hydroxy, halo, haloalkyl, alkoxy, —SH, —S-(alkyl), —SeH, —Se-(alkyl), aryl, heteroaryl, cycloalkyl, heterocycloalkyl, amino, carboxylic acid, ester, guanidino, and amido; and
R3 is H or alkyl optionally substituted with one or more substituents selected from hydroxy, halo, haloalkyl, alkoxy, —SH, —S-(alkyl), —SeH, —Se-(alkyl), aryl, heteroaryl, cycloalkyl, heterocycloalkyl, amino, carboxylic acid, ester, guanidino, and amido;
or R1 and R3 are taken together with the intervening atoms to form a 5- to 7-membered ring, wherein the 5- to 7-membered ring is optionally substituted with one or more substituents selected from hydroxy, halo, haloalkyl, alkoxy, —SH, —S-(alkyl), —SeH, —Se-(alkyl), aryl, heteroaryl, cycloalkyl, heterocycloalkyl, amino, carboxylic acid, ester, guanidino, and amido; and
R4 is H or (C1-C6)alkyl.

### Claim at position 2

2-5. (canceled)

### Claim 6 (depends on 1)

The compound of claim 1, having a structure of formula (Ie):

### Claim at position 4

7-10. (canceled)

### Claim 11 (depends on 6)

The compound of claim 6, wherein Rb is H or alkyl or acyl.

### Claim 12 (depends on 11)

The compound of claim 11, wherein Rb is H.

### Claim 13 (depends on 6)

The compound of claim 6, wherein X is O.

### Claim 14 (depends on 6)

The compound of claim 6, wherein R1 is H.

### Claim 15 (depends on 6)

The compound of claim 6, wherein R1 is aralkyl, heteroaralkyl, (cycloalkyl)alkyl, or (heterocycloalkyl)alkyl.

### Claim at position 10

16-23. (canceled)

### Claim 24 (depends on 6)

The compound of claim 6, wherein R1 is an amino acid side chain of Arg, His, Lys, Asp, Glu, Ser, Thr, Asn, Gin, Cys, Sec, Gly, Ala, Val, Ile, Leu, Met, Phe, Tyr, or Trp.

### Claim 25 (depends on 6)

The compound of claim 6, wherein R3 is H.

### Claim at position 13

26-29. (canceled)

### Claim 30 (depends on 6)

The compound of claim 6, wherein R4 is methyl, ethyl, propyl, or isopropyl.

### Claim 31 (depends on 6)

The compound of claim 6, wherein R4 is ethyl.

### Claim 32 (depends on 1)

The compound of claim 1, having the following structure:
or a pharmaceutically acceptable salt thereof.

### Claim 33

(canceled)

### Claim 34 (depends on 1)

The compound of claim 1, having the following structure:
or a pharmaceutically acceptable salt thereof.

### Claim 35 (depends on 1)

The compound of claim 1, having the following structure:
or a pharmaceutically acceptable salt thereof.

### Claim 36

(canceled)

### Claim 37 (depends on 1)

The compound of claim 1, having the following structure:
or a pharmaceutically acceptable salt thereof.

### Claim 38 (depends on 6)

A solid pharmaceutical composition comprising a compound of claim 6 and a pharmaceutically acceptable carrier.

### Claim 39 (depends on 1)

A method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1.

### Claim at position 24

40-48. (canceled)

### Claim 49 (depends on 1)

The compound of claim 1, having the following structure:
or a pharmaceutically acceptable salt thereof.

### Claim 50 (depends on 1)

The compound of claim 1, having the following structure:
or a pharmaceutically acceptable salt thereof.

### Claim 51 (depends on 1)

The compound of claim 1, having the following structure:
or a pharmaceutically acceptable salt thereof.

### Claim 52 (depends on 1)

The compound of claim 1, having the following structure:
or a pharmaceutically acceptable salt thereof.
